Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Oncocyte Corp (OCX)

Oncocyte Corp (OCX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 101,347
  • Shares Outstanding, K 51,973
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,750 K
  • 60-Month Beta 4.81
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.11
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.50 +30.00%
on 09/10/19
2.37 -17.72%
on 08/14/19
-0.32 (-14.10%)
since 08/13/19
3-Month
1.50 +30.00%
on 09/10/19
4.33 -54.97%
on 06/21/19
-1.83 (-48.41%)
since 06/13/19
52-Week
1.16 +67.38%
on 12/14/18
6.92 -71.82%
on 01/29/19
-0.35 (-15.22%)
since 09/13/18

Most Recent Stories

More News
Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced the pricing of the sale of 4,000,000...

OCX : 1.95 (unch)
OncoCyte to Report Second Quarter 2019 Financial Results on Wednesday, August 14, 2019

OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the second...

OCX : 1.95 (unch)
Lifshitz & Miller LLP Announces Investigation of Acer Therapeutics Inc., Aclaris Therapeutics, Inc., Ideanomics, Inc., L Brands, Inc., Marriott International, Inc., NRC Group Holdings Corp., Omnicell, Inc., and OncoCyte Corporation

Acer Therapeutics Inc. (ACER)

OMCL : 73.72 (+1.28%)
OCX : 1.95 (unch)
LB : 18.87 (-0.74%)
IDEX : 1.62 (+0.62%)
ACRS : 1.03 (-4.63%)
MAR : 133.99 (+1.12%)
OncoCyte Strengthens Board of Directors with Addition of Industry Veteran Melinda Griffith

OncoCyte Corporation (NYSE American: OCX), a developer of novel, molecular diagnostic tests for the early detection and management of cancer, today announced the appointment of Melinda Griffith to its...

OCX : 1.95 (unch)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OncoCyte Corporation - OCX

Pomerantz LLP is investigating claims on behalf of investors of OncoCyte Corporation ("OncoCyte" or the "Company") (NYSEAMERICAN: OCX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

OCX : 1.95 (unch)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OncoCyte Corporation - OCX

Pomerantz LLP is investigating claims on behalf of investors of OncoCyte Corporation ("OncoCyte" or the "Company") (NYSEAMERICAN: OCX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

OCX : 1.95 (unch)
OncoCyte Provides Mid-Year Update

OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today provided a mid-year update and announced that the Company will require additional...

OCX : 1.95 (unch)
OncoCyte (OCX) Catches Eye: Stock Jumps 7.3%

OncoCyte (OCX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

NTRA : 32.76 (+0.74%)
OCX : 1.95 (unch)
OncoCyte Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 14, 2019 / OncoCyte Corp. (NYSEMKT: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 4:30 PM Eastern Time.

OCX : 1.95 (unch)
OncoCyte to Report First Quarter 2019 Financial Results on Tuesday, May 14

OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the first...

OCX : 1.95 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade OCX with:

Business Summary

OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California.

See More

Key Turning Points

2nd Resistance Point 2.13
1st Resistance Point 2.04
Last Price 1.95
1st Support Level 1.87
2nd Support Level 1.79

See More

52-Week High 6.92
Fibonacci 61.8% 4.72
Fibonacci 50% 4.04
Fibonacci 38.2% 3.36
Last Price 1.95
52-Week Low 1.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar